Breaks Categories: News

TuesdaySep 28, 2021 10:11 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the gold-winning U.S. men’s basketball team at the 2004 Athens Olympics. In 2015, Odom was hospitalized in Las Vegas after a near-death overdose resulting in multiple seizures, strokes and a coma. An upcoming documentary…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

MondaySep 20, 2021 1:11 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to open 15 additional clinics in the next 18 months. KWC’s ketamine infusion treatment clinics are located in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington; Delic’s clinics are in California and Arizona. “This is a game changer for the future of health and psychedelic wellness in America,” said Delic cofounder and…

Continue Reading

ThursdaySep 16, 2021 10:27 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, will be a featured presenter at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The three-day event, scheduled for Sept. 20–23, 2021, will be a virtual event. Tryp CEO and chair Greg McKee will be part of the agenda with a company presentation slated to begin on Sept. 21 at 3:35 p.m EDT. The presentation will include a company overview as well as a discussion about Tryp’s pipeline as well as its for psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”)…

Continue Reading

FridaySep 10, 2021 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Keynote Speaker Chris Ryan, Ph.D., for World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Chris Ryan, Ph.D., will serve as one of the headline speakers on Nov. 7, 2021, at Meet Delic, the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business. In his keynote, “Psychedelics and the Search for Truth,” Ryan will explore the emerging potential for psychedelics to reshape the modern world. Ryan is the New York Times best-selling co-author of “Sex at Dawn: How We Mate, Why We Stray, and What it Means for Modern Relationships.” He also hosts…

Continue Reading

ThursdaySep 09, 2021 11:58 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Share Company’s Mission, iSTRYM Developments at 2021 SANA Symposium

MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced its presence at the 2021 SANA Symposium as a platinum sponsor and host of the Innovation Theater. According to the update, MINDCURE will be engaging with clinicians around the world interested in learning more about psychedelic-assisted psychotherapy, and specifically in adopting novel protocols and practice standards around psychedelics. The timing of the conference coincides with the company’s recent release of its digital therapeutics (“DTx”) platform for psychedelics — iSTRYM — into partner clinics across North America. “We could not ask for a better time or…

Continue Reading

FridaySep 03, 2021 11:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature,…

Continue Reading

WednesdaySep 01, 2021 11:28 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO of Tryp, will provide an overview of the company and its pipeline including Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN”(TM)) program for chronic pain and eating disorder indications. Interested parties should visit https://ibn.fm/AkhYM to register and access the presentation. In addition, Tryp announced that it has granted an…

Continue Reading

MondayAug 30, 2021 1:46 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights Announces Upcoming DMT Conference

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting next month’s DMT Conference. Held in an entirely virtual format, the conference is slated for  Sept. 9–10, 2021. According to the announcement, the event will focus on the potential of dimethyltryptamine (“DMT”) regarding drug development and safety, clinical care, law and regulation, business and markets, science and research. The DMT conference is part of Microdose’s Molecular Masterclasses conference events, a speaker series designed for deep dives into the world's favorite…

Continue Reading

MondayAug 30, 2021 9:30 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically covers the psychedelic renaissance and digs deeper into what has happened to the psychedelic industry from 2017 to 2020. The two-part series captures key moments in the history of the psychedelic sector, as well as providing a brief outline of  those events and the state…

Continue Reading